Company intelligence / Profile preview

Astraris

Burlington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Astraris, Inc. was a private biotechnology company active in the mid-2000s that focused on the development of vascular disrupting technologies for the treatment of solid tumors. The company aimed to advance oncology investigational drugs through clinical development stages, specifically targeting the vasculature of cancerous growths to inhibit tumor progression. Led by experienced pharmaceutical executives, Astraris operated as an early-stage startup before its leadership transitioned to other prominent biopharmaceutical firms. The company is no longer active in the biotechnology sector.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Astraris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astraris.

Explore the full profile